Search Results - "Rutgers, EJ"

Changes over time in the impact of gene‐expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study by Kuijer, A., Drukker, C.A., Elias, S.G., Smorenburg, C.H., Th. Rutgers, E.J., Siesling, S., van Dalen, Th

“…Ten years ago gene‐expression profiles were introduced to aid adjuvant chemotherapy decision making in breast cancer. Since then subsequent national guidelines…”
Get full text

Associations of a breast cancer polygenic risk score with tumor characteristics and survival by Lopes Cardozo, Josephine, Andrulis, Irene L., Peter, Devilee, Dörk, Thilo, Drukker, Caroline, Fasching, Peter A., Hooning, Maartje J., Keeman, Renske, Nevanlinna, Heli, Rutgers, Emiel J., van 't Veer, Laura, Hall, Per, Bojesen, Stig Egil, Douglas, Easton, Eccles, Diana, Pharoah, Paul, Schmidt, Marjanka

“…563 Background: A polygenic risk score (PRS) consisting of 313 single nucleotide polymorphisms (PRS 313 ) is associated with risk of breast cancer and…”
Get full text

First results of the preoperative accelerated partial breast irradiation (PAPBI) trial by van der Leij, Femke, Bosma, Sophie C.J, van de Vijver, Marc J, Wesseling, Jelle, Vreeswijk, Sandra, Rivera, Sofia, Bourgier, Celine, Garbay, Jean-Rémi, Foukakis, Theodoros, Lekberg, Tobias, van den Bongard, Desiree H.J.G.D, van Vliet-Vroegindeweij, Corine, Bartelink, Harry, Rutgers, Emiel J, Elkhuizen, Paula H.M

“…Abstract Background and purpose The aim of this study is to assess the toxicity and cosmetic outcome of preoperative accelerated partial breast irradiation…”
Get full text

Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer by Retèl, VP, Joore, MA, van 't Veer, LJ, Cardoso, F, Piccart, MJ, Rutgers, EJ, Tryfonidis, K, Poncet, C, van Harten, WH

“…Abstract Rationale: The 70-gene signature (MammaPrint®, MP) is a prognostic test which guides treatment decisions in patients with early breast cancer. After…”
Get full text

Abstract P3-03-06: Internal mammary chain sentinel nodes in early stage breast cancer patients: Towards selective removal by van Loevezijn, AA, Bartels, SA, van Duijnhoven, FH, Heemsbergen, WD, Bosma, SC, Elkhuizen, PH, Donswijk, ML, Rutgers, EJ, Oldenburg, HS, Vrancken Peeters, M-JT, van der Ploeg, IM

“…Abstract Background Internal mammary chain (IMC) sentinel nodes (SN) are visible in 1 out of 5 breast cancer patients on lymph scintigraphy after intra- or…”
Get full text

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) by van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

“…Dose-dense administration of chemotherapy and the addition of taxanes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival…”
Get full text

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MIND ACT trial by Aalders, KC, Kuijer, A, Straver, ME, Slaets, L, Litiere, S, Viale, G, van't Veer, LJ, Glas, AM, Delorenzi, M, vanDalen, T, Tryfonidis, K, Piccart, MJ, Cardoso, F, Rutgers, EJ

“…Background: In multifocal breast cancer, guidelines recommend basing adjuvant systemic treatment decisions on characteristics of the largest lesion,…”
Get full text

Abstract P6-13-01: MRI breast cancer screening compared to mammography in women with a familial risk: A multicenter randomized controlled trial by Tilanus-Linthorst, MM, Saadatmand, S, Geuzinge, AH, Rutgers, EJ, Mann, R, de Roy van Zuidewijn, DB, Zonderland, HM, Tollenaar, RA, Lobbes, MB, Ausems, MG, van 't Riet, M, Hooning, MJ, Mares-Engelbert, I, Luiten, EJ, Heijnsdijk, EA, Verhoef, C, Karssemeijer, N, Oosterwijk, JC, Obdeijn, I-M, de Koning, HJ

“…Abstract Background: Screening guidelines for women with a family history of breast cancer without a known causative gene mutation differ per country. No…”
Get full text

Abstract GS4-01: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023) by Rutgers, EJ, Donker, M, Poncet, C, Straver, ME, Meijnen, P, van de Velde, CJ, Mansel, RE, Blanken, C, Orzalesi, L, Klinkenbijl, JH, van der Mijle, HC, Veltkamp, SC, van 't Riet, M, Albregts, M, Marinelli, A, Rijna, H, Tobon Morales, R, Snoj, M, Bundred, N, Chauvet, MP, Merkus, JW, Petignat, P, Schinagl, DA, Coens, C, Peric, A, Bogaerts, J, van Tienhoven, G

“…Abstract Background: Sentinel node biopsy (SNB) is standard in assessing axillary lymph node status in patients with clinically node-negative breast cancer…”
Get full text

Abstract PD7-01: Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial by Cardoso, F, Slaets, L, de Snoo, F, Bogaerts, J, van 't Veer, LJ, Rutgers, EJ, Piccart-Gebhart, MJ, Stork-Sloots, L, Russo, L, Dell'Orto, P, Viale, G

“…Abstract Background Molecular subgroups within early breast cancer (EBC), such as Luminal A, Luminal B, HER-2+, Basal-like may help to best to identify…”
Get full text

Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area by Schreuder, K., Kuijer, A., Rutgers, E.J. Th, Smorenburg, C.H., van Dalen, Th, Siesling, S.

“…In Dutch guidelines, gene expression profiles (GEP) are indicated in estrogen receptor positive early breast cancer patients in whom benefit of chemotherapy…”
Get full text

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) by van Rossum, AGH, Oosterkamp, HM, van Werkhoven, E, Opdam, M, Mandjes, IAM, van Leeuwen-Stok, E, van Tinteren, H, Kok, M, Imholz, ALT, Portielje, JEA, Bos, MMEM, van Bochove, A, Wesseling, J, Rutgers, EJ, Rodenhuis, S, Linn, SC

“…Abstract Background: Anthracycline-based adjuvant chemotherapy has substantially improved breast cancer survival. Both the addition of taxanes as well as using…”
Get full text

Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer by Hannemann, Juliane, Oosterkamp, Hendrika M, Bosch, Cathy A J, Velds, Arno, Wessels, Lodewyk F A, Loo, Claudette, Rutgers, Emiel J, Rodenhuis, Sjoerd, van de Vijver, Marc J

“…At present, clinically useful markers predicting response of primary breast carcinomas to either doxorubicin-cyclophosphamide (AC) or doxorubicin-docetaxel…”
Get full text

Abstract P3-02-09: Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition by Saadatmand, S, Heijnsdijk, EA, Rutgers, EJ, Hoogerbrugge, N, Oosterwijk, JC, Tollenaar, RA, Hooning, M, Obdeijn, I-M, de Koning, HJ, Tilanus-Linthorst, MM

“…Abstract Background: To reduce mortality risk, women with a family history of breast cancer are often screened with mammography before 50 years of age…”
Get full text

Abstract P6-06-13: Optimized prediction of clinical outcome by the PREDICT plus tool and the 70-gene signature in early stage node-negative breast cancer by Drukker, CA, Nijenhuis, MV, Bueno-de-Mesquita, JM, Retel, VP, van Tinteren, H, Schmidt, MK, van Harten, WH, Sonke, GS, van 't Veer, LJ, Rutgers, EJ, van de Vijver, MJ, Linn, SC

“…Abstract Background Established breast cancer guidelines and online tools use clinico-pathological factors including age, tumor size and grade to evaluate the…”
Get full text

P2-09-06: Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT during Neoadjuvant Chemotherapy by Koolen, BB, Pengel, KE, Wesseling, J, Vogel, WV, Vrancken, Peeters M-JT, Gilhuijs, KG, Rutgers, EJ, Valdés, Olmos RA

“…Abstract Background - Neoadjuvant chemotherapy (NAC) is increasingly applied in stage II and III breast cancer. Response monitoring with magnetic resonance…”
Get full text

Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers by WEIGELT, B, VERDUIJN, P, BOSMA, A. J, RUTGERS, E. J, PETERSE, H. L, VAN'T VEER, L. J

“…Disseminated breast tumour cells in sentinel lymph nodes (SNs) were evaluated by quantitative real-time PCR and the sensitivity of this assay was compared to…”
Get full text

Accuracy of MRI in selecting patients for breast conserving therapy after neoadjuvant chemotherapy by Straver, ME, Loo, CE, Vrancken-Peeters, MT, Rutgers, EJ, Gilhuijs, K

“…Abstract Abstract #4006 Introduction: Accurate assessment of the extent of residual breast cancer is crucial for the surgical planning after neoadjuvant…”
Get full text

Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention by Esserman, LJ, van't Veer, LJ, Perou, C, Rutgers, EJ, Davis, SE

“…Abstract Abstract #6034 Population screening has increased the absolute number of breast cancer cases. In spite of widespread screening, there are still many…”
Get full text

Abstract P4-11-01: Rapid genetic counseling and testing in newly diagnosed breast cancer patients, findings from an RCT by Wevers, MR, Ausems, MG, Bleiker, EM, Rutgers, EJ, Witkamp, AJ, Hahn, DE, Brouwer, T, Kuenen, MA, van der Sanden-Melis, J, van der Luijt, RB, Hogervorst, FB, van Dalen, T, Theunissen, EB, van Ooijen, B, de Roos, MA, Borgstein, PJ, Vrouenraets, BC, Huisman, JJ, Bouma, WH, Rijna, H, Vente, JP, Valdimarsdottir, H, Verhoef, S, Aaronson, NK

“…Abstract Introduction: Female breast cancer patients carrying a BRCA1/2 mutation have an increased risk of second primary breast and ovarian tumors. Rapid…”
Get full text